Savatier P, Lapillonne H, van Grunsven L A, Rudkin B B, Samarut J
Laboratoire de Biologie Moléculaire et Cellulaire-UMR 49 CNRS-LA INRA, Ecole Normale Supérieure de Lyon, France.
Oncogene. 1996 Jan 18;12(2):309-22.
The expression of E and D-type cyclins, Cyclin-Dependent Kinase (CDK) 2 and 4, as well as CDK inhibitors p21Cip1 and p27Kip1 were examined during in vitro differentiation of mouse embryonic stem (ES) cells. ES cells cultured in presence of Differentiation Inhibitory Activity/Leukemia Inhibitory Factor (DIA/LIF) express very low levels of cyclin E/CDK2 complexes, p21Cip1 and p27Kip1 CDK inhibitors, while cyclin D/CDK4-associated kinase activity is undetectable. Withdrawal of DIA/LIF, which induces differentiation, results in the progressive up-regulation of all. Up-regulation of D cyclins occurs through an increase in the steady-state levels of mRNA, concomitantly with the activation of Brachyury and Goosecoid, two early markers of mesoderm differentiation. Similarly, cells from the epiblast of the early postimplantation mouse embryo do not express any cyclin D/CDK4 complexes. These are progressively upregulated at gastrulation and early organogenesis. DIA/LIF-stimulated ES cells are not growth-arrested by overexpression of p16Ink4a, a specific inhibitor of CDK4 and CDK6. We propose that the G1/S transition may be regulated by a minimal mechanism in mouse embryonic stem cells. Induction of differentiation triggers the establishment of a more sophisticated mechanism involving both cyclin D/CDK4- and CDK inhibitor-associated control of G1-phase progression.
在小鼠胚胎干细胞的体外分化过程中,检测了E型和D型细胞周期蛋白、细胞周期蛋白依赖性激酶(CDK)2和4以及CDK抑制剂p21Cip1和p27Kip1的表达。在存在分化抑制活性/白血病抑制因子(DIA/LIF)的情况下培养的胚胎干细胞表达极低水平的细胞周期蛋白E/CDK2复合物、p21Cip1和p27Kip1 CDK抑制剂,而细胞周期蛋白D/CDK4相关激酶活性则检测不到。去除诱导分化的DIA/LIF会导致所有这些蛋白的逐渐上调。D型细胞周期蛋白的上调是通过mRNA稳态水平的增加实现的,同时伴随着中胚层分化的两个早期标志物Brachyury和Goosecoid的激活。同样,植入后早期小鼠胚胎外胚层的细胞不表达任何细胞周期蛋白D/CDK4复合物。这些复合物在原肠胚形成和早期器官发生过程中逐渐上调。DIA/LIF刺激的胚胎干细胞不会因p16Ink4a(一种CDK4和CDK6的特异性抑制剂)的过表达而生长停滞。我们提出,在小鼠胚胎干细胞中,G1/S转换可能受一种最小机制调控。分化诱导触发了一种更复杂机制的建立,该机制涉及细胞周期蛋白D/CDK4和CDK抑制剂相关的G1期进程控制。